JP7599425B2 - トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 - Google Patents

トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 Download PDF

Info

Publication number
JP7599425B2
JP7599425B2 JP2021540103A JP2021540103A JP7599425B2 JP 7599425 B2 JP7599425 B2 JP 7599425B2 JP 2021540103 A JP2021540103 A JP 2021540103A JP 2021540103 A JP2021540103 A JP 2021540103A JP 7599425 B2 JP7599425 B2 JP 7599425B2
Authority
JP
Japan
Prior art keywords
vhh
seq
molecule
tfr
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021540103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518392A5 (cg-RX-API-DMAC7.html
JP2022518392A (ja
Inventor
ロミー コーエン,
マリオン ダヴィド,
ミシェル クレストシャティスキ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix-Marseille Université
Vect Horus
Original Assignee
Aix-Marseille Université
Vect Horus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix-Marseille Université, Vect Horus filed Critical Aix-Marseille Université
Publication of JP2022518392A publication Critical patent/JP2022518392A/ja
Publication of JP2022518392A5 publication Critical patent/JP2022518392A5/ja
Application granted granted Critical
Publication of JP7599425B2 publication Critical patent/JP7599425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021540103A 2019-01-09 2020-01-08 トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 Active JP7599425B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305031 2019-01-09
EP19305031.7 2019-01-09
PCT/EP2020/050318 WO2020144233A1 (en) 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses

Publications (3)

Publication Number Publication Date
JP2022518392A JP2022518392A (ja) 2022-03-15
JP2022518392A5 JP2022518392A5 (cg-RX-API-DMAC7.html) 2022-12-19
JP7599425B2 true JP7599425B2 (ja) 2024-12-13

Family

ID=65236972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540103A Active JP7599425B2 (ja) 2019-01-09 2020-01-08 トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用

Country Status (9)

Country Link
US (1) US12152317B2 (cg-RX-API-DMAC7.html)
EP (1) EP3908608A1 (cg-RX-API-DMAC7.html)
JP (1) JP7599425B2 (cg-RX-API-DMAC7.html)
CN (1) CN113474369B (cg-RX-API-DMAC7.html)
AU (1) AU2020206593B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021013559A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124790A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020144233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
JP7652807B2 (ja) * 2020-06-24 2025-03-27 サプリーム テクノロジーズ,ベー.フェー. 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用
CA3202539A1 (en) * 2020-12-02 2022-06-09 University Health Network Methods and uses for ndfip1 fusion polypeptides in treating neurodegenerative diseases, brain and/or traumatic and non-traumatic spinal cord injuries, and/or optic neuropathies
MX2023015520A (es) * 2021-07-01 2024-01-22 Denali Therapeutics Inc Conjugados de oligonucleotidos dirigidos al receptor de transferrina.
TW202330591A (zh) * 2021-11-19 2023-08-01 日商Jcr製藥股份有限公司 人類運鐵蛋白受體親和性肽
JP7889887B2 (ja) * 2021-12-02 2026-07-14 リンノ ファーマシューティカルズ インコーポレイテッド トランスフェリン結合抗体及びその使用
US11939391B2 (en) * 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
US20250066449A1 (en) * 2021-12-31 2025-02-27 Imnewrun, Inc. Blood-brain barrier permeable fusion protein and uses thereof
EP4504950A1 (en) 2022-04-01 2025-02-12 Takeda Pharmaceutical Company Limited Gene therapy for diseases with cns manifestations
CN119213030A (zh) * 2022-05-16 2024-12-27 戴纳立制药公司 转铁蛋白受体结合结构域和包含其的蛋白
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
US20260116990A1 (en) 2022-11-23 2026-04-30 Key2Brain Ab Vhh antibodies and uses thereof
EP4622668A1 (en) 2022-11-23 2025-10-01 Key2Brain AB Vhh antibodies and uses thereof
KR20250114322A (ko) * 2022-12-02 2025-07-29 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-tfr1 항체 및 이의 용도
TW202436352A (zh) * 2023-02-07 2024-09-16 日商Jcr製藥股份有限公司 人類運鐵蛋白受體親和性肽
CN116179607A (zh) * 2023-03-27 2023-05-30 迦进生物医药(上海)有限公司 一种human TfR2高表达的稳转细胞株及其构建方法和应用
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用
JP2026519919A (ja) 2023-04-03 2026-06-19 ブイアイビー ブイゼットダブリュ 血液脳関門通過抗体
EP4480965A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
CN121969643A (zh) 2023-06-22 2026-05-01 维克塔-霍洛斯公司 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗神经系统疾病的用途
EP4480964A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
WO2024261332A2 (en) 2023-06-22 2024-12-26 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
CN121773136A (zh) * 2023-07-04 2026-03-31 北京星奇原生物科技有限公司 抗-TfR1抗体及其用途
AU2024329222A1 (en) 2023-08-18 2026-02-12 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
US20250064958A1 (en) * 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025194170A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of immune-related membrane proteins
WO2025194171A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors
WO2025207959A1 (en) * 2024-03-27 2025-10-02 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
TW202602933A (zh) * 2024-03-28 2026-01-16 美商健臻公司 與轉鐵蛋白受體1的特異性表位結合的多肽
WO2025226642A1 (en) 2024-04-25 2025-10-30 Eli Lilly And Company Lipid nano delivery particles for targeted transport of nucleic acids and methods of making and using the same
WO2026142988A1 (en) * 2024-12-24 2026-07-02 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization of c-c chemokine receptor 6

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
JP2010533130A (ja) 2007-06-29 2010-10-21 インスティティ・パスツール 目的物質の送達用ペプチドベクターの製造のためのvhh抗体の使用及びその適用
JP2014500866A (ja) 2010-11-05 2014-01-16 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
JP2016501881A (ja) 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門(bbb)を透過する二重特異性結合タンパク質
WO2018031424A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008322523B2 (en) 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
DK2951201T3 (en) * 2013-01-30 2018-01-08 Vib Vzw Novel chimeric polypeptides for screening and drug detection purposes
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
EA035517B1 (ru) * 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
JP2010533130A (ja) 2007-06-29 2010-10-21 インスティティ・パスツール 目的物質の送達用ペプチドベクターの製造のためのvhh抗体の使用及びその適用
JP2014500866A (ja) 2010-11-05 2014-01-16 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
JP2016501881A (ja) 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門(bbb)を透過する二重特異性結合タンパク質
WO2018031424A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Also Published As

Publication number Publication date
CN113474369B (zh) 2024-09-03
EA202191893A1 (ru) 2021-12-02
BR112021013559A2 (pt) 2021-09-21
WO2020144233A1 (en) 2020-07-16
AU2020206593B2 (en) 2026-02-05
JP2022518392A (ja) 2022-03-15
US20220090050A1 (en) 2022-03-24
EP3908608A1 (en) 2021-11-17
AU2020206593A1 (en) 2021-07-15
US12152317B2 (en) 2024-11-26
CA3124790A1 (en) 2020-07-16
CN113474369A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
US12152317B2 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses
Stocki et al. Blood‐brain barrier transport using a high affinity, brain‐selective VNAR antibody targeting transferrin receptor 1
JP6541237B2 (ja) インスリン様成長因子1受容体特異的抗体及びそれらの使用
US20190374617A1 (en) Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
JP6541235B2 (ja) インスリン様成長因子1受容体特異的抗体及びそれらの使用
US20230414780A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses
US12037382B2 (en) Inverse agonistic anti-US28 antibodies
US20260062480A1 (en) Human blood-brain barrier targeting antibodies
US20240174755A1 (en) Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof
EP4480965A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
US20240325562A1 (en) Internalizing binding molecules
US12161889B2 (en) Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB
EA048741B1 (ru) Молекулы, связывающие рецептор трансферрина, их конъюгаты, и их применение
EP4731658A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat nervous system diseases
US20250352660A1 (en) Blood-nerve barrier targeting conjugates and methods of use
CN118139627A (zh) 使car t细胞恢复活力的缀合物、组合物和方法
JP2026512773A (ja) Rage受容体結合分子、そのコンジュゲート、および、肺疾患を検出、予防または治療するためのその使用
CN121794291A (zh) 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗肌肉疾病的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240806

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241203

R150 Certificate of patent or registration of utility model

Ref document number: 7599425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150